OBJECTIVES The aim of this study was to determine the risk of scaffold thrombosis (ST) after percutaneous coronary intervention (PCI) with placement of an ABSORB bioresorbable vascular scaffold (BVS) (Abbott Vascular, Santa Clara, California) by conducting a systematic review and meta-analysis.
and AMC (Academic Medical Center) registries (7,8), had alarmingly high rates of ST. Given the increased risk of ST after PCI for patients with ACS, especially after ST-segment elevation myocardial infarction (STEMI) (9), it is not surprising that the risk of ST with a BVS also increases in the hypercoagulable setting of ACS, given the greater strut thickness and higher risk of malapposition due to undersizing. Thus, concern has been raised regarding the safety of BVSs with regard to ST, particularly in the setting of ACS (10,11).
Thus, we performed a systematic review and metaanalysis to assess the incidence of ST and other cardiovascular outcomes after PCI with placement of the ABSORB BVS and compare outcomes with patients who received DES.
METHODS
Two independent reviewers (MJL and HAB) systematically searched (July 2015) MEDLINE/PubMed and available abstract data, applying the search terms "bioresorbable" AND "scaffold". We limited our data to studies using the ABSORB BVS. We also obtained presentation slides of the late breaking clinical trials (including Euro PCR 2015 meeting). We included studies in human patients: 1) that underwent PCI for obstructive coronary artery disease;
2) with at least 1 month clinical follow-up data; and 3) included patients who underwent placement of the ABSORB BVS. We excluded studies with inadequate data for abstraction, duplication of data, case reports and case series, studies using other bioresorbable scaffolds (polymer or metallic), and studies using metallic stents with bioresorbable polymer coating. Baseline study characteristics are shown in Table 1 , baseline patient characteristics are shown in Table 2 , and lesion characteristics for lesions treated with a BVS are shown in Table 3 . The patients included in our study had a pooled mean AE SD age of 60 AE 11 years, 78% were male, 18% had a previous MI, 64% had hypertension, 59% had hyperlipidemia, 22% had diabetes mellitus, and 40% were current smokers. PCI for stable angina was performed in 36% of patients, and 59% underwent PCI for ACS (14% for unstable angina, 18% for non-STEMI, and 27% for STEMI). Table 3 .
A summary of the study-level outcomes is shown in ST at 1 month among 8,156 patients, for an incidence of 1.4% (9). Thus, it is not surprising that our study showed a trend toward an increased incidence of definite/probable ST for both BVSs and DES for studies with a greater proportion of ACS patients.
The incidence of ST among patients with DES in our meta-analysis was also fairly low, consistent with Lipinski et al. Forrest plots comparing definite/probable scaffold thrombosis, definite scaffold thrombosis, and 1 month (acute and subacute) scaffold thrombosis during follow-up for patients who received a BVS compared with patients who received DES. Studies were divided into subgroups based on whether they were a randomized, controlled trials (RCT) or nonrandomized, controlled trials (non-RCT). Abbreviations as in Figure 4 .
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identified as a mechanism of very late ST (50 WHAT IS NEXT? Further randomized, controlled trials, especially in patients with ACS, are needed to assess the risk of ST after PCI.
